GlassScriptPhysician profile
Alex Ray Kirby
NPI 1356305676
$8,404.57
in general payments reported to CMS, 2019-2025
38 companies · $670 in 2025
The $670 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $888 · 2021: $1,032 · 2022: $1,572 · 2023: $2,009 · 2024: $782 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148 · Travel and Lodging: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,148.13 |
| Travel and Lodging | $312.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,425.51 | 2019-2025 | Watchman Access System, General - Therapies |
| Abbott Laboratories | $918.27 | 2019-2025 | Amplatzer Amulet, Amplatzer Talisman, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $648.49 | 2019-2025 | Impella |
| Heartflow, INC. | $635.37 | 2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $523.93 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $412.04 | 2019-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $411.86 | 2021-2024 | Symplicity G3, Micra, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $382.74 | 2019-2025 | |
| Amgen INC. | $368.81 | 2019-2025 | Repatha |
| Actelion Pharmaceuticals US, INC. | $301.96 | 2019-2023 | Opsumit |
| Shockwave Medical, INC | $289.53 | 2021-2025 | |
| Medtronic Vascular, INC. | $232.66 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $230.48 | 2019-2025 | Lifevest |
| Philips North America LLC | $230.06 | 2020-2025 | Coronary Other, Fleet Management |
| Merck Sharp & Dohme LLC | $201.15 | 2021-2025 | Verquvo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Kirby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.